Outcome of Innate Pharma’s 2025 Annual General Meeting

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 22, 2025, in Marseille. All resolutions were voted.

A total of 114 votes were cast out of a total of 43,447,237 shares giving right to 43,535,215 voting rights, representing a quorum of 47,14%.
Following the approval of its shareholders at the Annual General Meeting held on May 22, 2025, the Company has transitioned from an Executive Board and Supervisory Board corporate governance structure to a Board of Directors structure with a Chief Executive Officer.

New Governance Structure

The newly appointed Board of Directors comprises:
-    Mrs. Irina Staatz-Granzer ;
-    Mr. Jonathan Dickinson ;
-    Mrs. Véronique Chabernaud;
-    Mrs. Pascale Boissel;
-    Mrs. Sally Bennett;
-    Mr. Christian Itin;
-    Mr. Marty J. Duvall;
-    Bpifrance Participations, represented by Mr. Olivier Martinez;

The Board of Directors then decided, on May 22, 2025, following the Annual General Meeting, to separate the functions of Chairman of the Board and Chief Executive Officer and appointed Mrs Irina Staatz Granz as Chairman of the Board and Mr Jonathan Dickinson as Chief Executive Officer.

“This evolution marks a new key milestone for Innate Pharma. It reflects our commitment to adopting a governance model aligned with international standards, while continuing to create value for all our stakeholders,” said Irina Staatz Granzer, Chairwoman of the Board of Directors.

The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2025 section of the Company’s website.